The path to successful commercialization of cell and gene therapies: empowering patient advocates.

[1]  Georg N Duda,et al.  Strategies for Derisking Translational Processes for Biomedical Technologies. , 2017, Trends in biotechnology.

[2]  P. Reinke,et al.  Overcoming Challenges Facing Advanced Therapies in the EU Market. , 2016, Cell stem cell.

[3]  P. Knoepfler,et al.  Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. , 2016, Cell stem cell.

[4]  Petra Reinke,et al.  Putting a price tag on novel autologous cellular therapies. , 2016, Cytotherapy.

[5]  D. Marshall,et al.  Cell & gene therapies and the evolving role of personalized medicine , 2016 .

[6]  I. Budin-Ljøsne,et al.  Patient and interest organizations’ views on personalized medicine: a qualitative study , 2016, BMC Medical Ethics.

[7]  Richard T. Lee,et al.  Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines , 2016, Stem cell reports.

[8]  M. Porteus.  Towards a new era in medicine: therapeutic genome editing , 2015, Genome Biology.

[9]  Aaron D. Levine,et al.  Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. , 2015, Cytotherapy.

[10]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[11]  Christine Y. Lu,et al.  Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries , 2015, PloS one.

[12]  Petra Reinke,et al.  Gene therapy: a possible future standard for HIV care. , 2015, Trends in biotechnology.

[13]  David Meyre,et al.  From big data analysis to personalized medicine for all: challenges and opportunities , 2015, BMC Medical Genomics.

[14]  M. Porteus,et al.  Genome editing of the germline: broadening the discussion. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  P. Knoepfler.  From bench to FDA to bedside: US regulatory trends for new stem cell therapies. , 2015, Advanced drug delivery reviews.

[16]  Laurie Burke,et al.  Patient-Focused Drug Development: A New Direction for Collaboration , 2015, Medical care.

[17]  P. Kefalas,et al.  Reimbursement of licensed cell and gene therapies across the major European healthcare markets , 2015, Journal of market access & health policy.

[18]  C. Scott.  The Case for Stem Cell Counselors , 2014, Stem cell reports.

[19]  Petra Reinke,et al.  The business case for cell and gene therapies , 2014, Nature Biotechnology.

[20]  Timothy Caulfield,et al.  Stem cell tourism and public education: the missing elements. , 2014, Cell stem cell.

[21]  Sivanesan Dakshanamurthy,et al.  Big data: the next frontier for innovation in therapeutics and healthcare , 2014, Expert review of clinical pharmacology.

[22]  Commercialization and stem cell research: a review of emerging issues. , 2013 .

[23]  Jodi B Segal,et al.  Patient-reported Outcomes (PROs): Putting the Patient Perspective in Patient-centered Outcomes Research , 2013, Medical care.

[24]  G. T. Sharrer,et al.  Personalized medicine: ethics for clinical trials. , 2012, Methods in molecular biology.

[25]  D. Collyar,et al.  How have patient advocates in the United States benefited cancer research? , 2005, Nature Reviews Cancer.